{"transactions":[{"id":712986,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:34:18.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":107429,"price":0.31,"value":33302.99,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 11,509 by AM LLC, 72,676  by BV 2014, 4,845 by BV 2014(B), 2,499 by AM BV2014 and 15,900 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.295 to $0.3342 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"No shares held by AM LLC, BV 2014, BV 2014(B), AM BV2014 and MPM OIF."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001134657-26-000020","document":"form4-07082026_090715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000020/form4-07082026_090715.xml","form_type":"4"}},{"id":712985,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:34:18.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":35770,"price":0.32,"value":11446.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,832 by MPM Asset Management LLC (\"AM LLC\"), 24,197 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,614 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 833 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 5,294 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3128 to $0.3388 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 11,509 by AM LLC, 72,676 by BV 2014, 4,845 by BV 2014(B), 2,499 by AM BV2014 and 15,900 by MPM OIF."}],"balance_after":107429,"source":{"system":"sec-edgar","filing":"0001134657-26-000020","document":"form4-07082026_090715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000020/form4-07082026_090715.xml","form_type":"4"}},{"id":724493,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T23:07:26.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":157084,"price":0.3,"value":47125.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 16,830 by MPM Asset Management LLC (\"AM LLC\"), 106,262 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 7,087 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 3,657 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 23,248 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2703 to $0.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 15,341 by AM LLC, 96,873 by BV 2014, 6,459 by BV 2014(B), 3,332 by AM BV2014 and 21,194 by MPM OIF."}],"balance_after":143199,"source":{"system":"sec-edgar","filing":"0001134657-26-000019","document":"form4-06292026_110612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000019/form4-06292026_110612.xml","form_type":"4"}},{"id":730215,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T22:59:23.000Z","date":"2026-06-17","kind":"sale","planned":false,"acquired":false,"shares":27695,"price":0.35,"value":9693.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":303719,"source":{"system":"sec-edgar","filing":"0001231919-26-000688","document":"form4-06222026_100616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000688/form4-06222026_100616.xml","form_type":"4"}},{"id":730214,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T22:59:23.000Z","date":"2026-06-17","kind":"sale","planned":false,"acquired":false,"shares":389216,"price":0.35,"value":136225.6,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":4268448,"source":{"system":"sec-edgar","filing":"0001231919-26-000688","document":"form4-06222026_100616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000688/form4-06222026_100616.xml","form_type":"4"}},{"id":735971,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:01:18.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":9939,"price":0.37,"value":3677.43,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3584 to $0.3906 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":331414,"source":{"system":"sec-edgar","filing":"0001231919-26-000654","document":"form4-06162026_100612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000654/form4-06162026_100612.xml","form_type":"4"}},{"id":735970,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:01:18.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":139686,"price":0.37,"value":51683.82,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3584 to $0.3906 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":4657664,"source":{"system":"sec-edgar","filing":"0001231919-26-000654","document":"form4-06162026_100612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000654/form4-06162026_100612.xml","form_type":"4"}},{"id":735969,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:01:18.000Z","date":"2026-06-15","kind":"sale","planned":false,"acquired":false,"shares":8554,"price":0.39,"value":3336.06,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3757 to $0.3955 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":341353,"source":{"system":"sec-edgar","filing":"0001231919-26-000654","document":"form4-06162026_100612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000654/form4-06162026_100612.xml","form_type":"4"}},{"id":735968,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:01:18.000Z","date":"2026-06-15","kind":"sale","planned":false,"acquired":false,"shares":120216,"price":0.39,"value":46884.24,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3757 to $0.3955 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":4797350,"source":{"system":"sec-edgar","filing":"0001231919-26-000654","document":"form4-06162026_100612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000654/form4-06162026_100612.xml","form_type":"4"}},{"id":735967,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:01:18.000Z","date":"2026-06-12","kind":"sale","planned":false,"acquired":false,"shares":11322,"price":0.4,"value":4528.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3814 to $0.4129 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":349907,"source":{"system":"sec-edgar","filing":"0001231919-26-000654","document":"form4-06162026_100612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000654/form4-06162026_100612.xml","form_type":"4"}},{"id":735966,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:01:18.000Z","date":"2026-06-12","kind":"sale","planned":false,"acquired":false,"shares":159119,"price":0.4,"value":63647.6,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3814 to $0.4129 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":4917566,"source":{"system":"sec-edgar","filing":"0001231919-26-000654","document":"form4-06162026_100612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000654/form4-06162026_100612.xml","form_type":"4"}},{"id":741377,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T00:13:56.000Z","date":"2026-06-11","kind":"sale","planned":false,"acquired":false,"shares":17437,"price":0.38,"value":6626.06,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3945 to $0.3636 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":361229,"source":{"system":"sec-edgar","filing":"0001231919-26-000628","document":"form4-06122026_120649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000628/form4-06122026_120649.xml","form_type":"4"}},{"id":741376,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T00:13:56.000Z","date":"2026-06-11","kind":"sale","planned":false,"acquired":false,"shares":245066,"price":0.38,"value":93125.08,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3945 to $0.3636 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":5076685,"source":{"system":"sec-edgar","filing":"0001231919-26-000628","document":"form4-06122026_120649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000628/form4-06122026_120649.xml","form_type":"4"}},{"id":741375,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T00:13:56.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":3051,"price":0.37,"value":1128.87,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3627 to $0.3791 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":378666,"source":{"system":"sec-edgar","filing":"0001231919-26-000628","document":"form4-06122026_120649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000628/form4-06122026_120649.xml","form_type":"4"}},{"id":741374,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T00:13:56.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":42872,"price":0.37,"value":15862.64,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3627 to $0.3791 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":5321751,"source":{"system":"sec-edgar","filing":"0001231919-26-000628","document":"form4-06122026_120649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000628/form4-06122026_120649.xml","form_type":"4"}},{"id":741373,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T00:13:56.000Z","date":"2026-06-09","kind":"sale","planned":false,"acquired":false,"shares":24565,"price":0.37,"value":9089.05,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.3791 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":381717,"source":{"system":"sec-edgar","filing":"0001231919-26-000628","document":"form4-06122026_120649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000628/form4-06122026_120649.xml","form_type":"4"}},{"id":741372,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T00:13:56.000Z","date":"2026-06-09","kind":"sale","planned":false,"acquired":false,"shares":345235,"price":0.37,"value":127736.95,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.3791 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":5364623,"source":{"system":"sec-edgar","filing":"0001231919-26-000628","document":"form4-06122026_120649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000628/form4-06122026_120649.xml","form_type":"4"}},{"id":743525,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T21:20:54.000Z","date":"2026-06-09","kind":"sale","planned":true,"acquired":false,"shares":76928,"price":0.37,"value":28463.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 8,242 by MPM Asset Management LLC (\"AM LLC\"), 52,039 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 3,471 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,791 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 11,385 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3553 to $0.3851 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 32,171 by AM LLC, 203,135 by BV 2014, 13,546 by BV 2014(B), 6,989 by AM BV2014 and 44,442 by MPM OIF."}],"balance_after":300283,"source":{"system":"sec-edgar","filing":"0001134657-26-000018","document":"form4-06102026_090649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000018/form4-06102026_090649.xml","form_type":"4"}},{"id":746641,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T22:13:23.000Z","date":"2026-06-08","kind":"sale","planned":true,"acquired":false,"shares":60547,"price":0.4,"value":24218.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,487 by AM LLC, 40,957 by BV 2014, 2,732 by BV 2014(B), 1,410 by AM BV2014 and 8,961 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3706 to $0.4126 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 40,413 by AM LLC, 255,174 by BV 2014, 17,017 by BV 2014(B), 8,780 by AM BV2014 and 55,827 by MPM OIF."}],"balance_after":377211,"source":{"system":"sec-edgar","filing":"0001134657-26-000017","document":"form4-06082026_100618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000017/form4-06082026_100618.xml","form_type":"4"}},{"id":746640,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T22:13:23.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":24946,"price":0.4,"value":9978.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 2,673 by AM LLC, 16,874 by BV 2014, 1,126 by BV 2014(B), 581 by AM BV2014 and 3,692 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3918 to $0.454 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 46,900 by AM LLC, 296,131 by BV 2014, 19,749 by BV 2014(B), 10,190 by AM BV2014 and 64,788 by MPM OIF."}],"balance_after":437758,"source":{"system":"sec-edgar","filing":"0001134657-26-000017","document":"form4-06082026_100618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000017/form4-06082026_100618.xml","form_type":"4"}},{"id":746639,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T22:13:23.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":20072,"price":0.44,"value":8831.68,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 2,150 by MPM Asset Management LLC (\"AM LLC\"), 13,578 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 906 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 467 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 2,971 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.4499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 49,573 by AM LLC, 313,005 by BV 2014, 20,875 by BV 2014(B), 10,771 by AM BV2014 and 68,480 by MPM OIF."}],"balance_after":462704,"source":{"system":"sec-edgar","filing":"0001134657-26-000017","document":"form4-06082026_100618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000017/form4-06082026_100618.xml","form_type":"4"}},{"id":752496,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T22:42:50.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":29749,"price":0.42,"value":12494.58,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,187 by AM LLC, 20,124 by BV 2014, 1,342 by BV 2014(B), 693 by AM BV2014 and 4,403 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.42 to $0.4367 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 51,723 by AM LLC, 326,583 by BV 2014, 21,781 by BV 2014(B), 11,238 by AM BV2014 and 71,451 by MPM OIF."}],"balance_after":482776,"source":{"system":"sec-edgar","filing":"0001134657-26-000016","document":"form4-06032026_100645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000016/form4-06032026_100645.xml","form_type":"4"}},{"id":752495,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T22:42:50.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":29595,"price":0.45,"value":13317.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,171 by AM LLC, 20,020 by BV 2014, 1,335 by BV 2014(B), 689 by AM BV2014 and 4,380 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4304 to $0.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 54,910 by AM LLC, 346,707 by BV 2014, 23,123 by BV 2014(B), 11,931 by AM BV2014 and 75,854 by MPM OIF."}],"balance_after":512525,"source":{"system":"sec-edgar","filing":"0001134657-26-000016","document":"form4-06032026_100645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000016/form4-06032026_100645.xml","form_type":"4"}},{"id":752494,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T22:42:50.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":80459,"price":0.47,"value":37815.73,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 8,620 by MPM Asset Management LLC (\"AM LLC\"), 54,428 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 3,630 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,873 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 11,908 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 58,081 by AM LLC, 366,727 by BV 2014, 24,458 by BV 2014(B), 12,620 by AM BV2014 and 80,234 by MPM OIF."}],"balance_after":542120,"source":{"system":"sec-edgar","filing":"0001134657-26-000016","document":"form4-06032026_100645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000016/form4-06032026_100645.xml","form_type":"4"}},{"id":759076,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T22:51:47.000Z","date":"2026-05-29","kind":"sale","planned":true,"acquired":false,"shares":32556,"price":0.45,"value":14650.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,488 by AM LLC, 22,023 by BV 2014, 1,469 by BV 2014(B), 758 by AM BV2014 and 4,818 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.44 to $0.4557 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 66,701 by AM LLC, 421,155 by BV 2014, 28,088 by BV 2014(B), 14,493 by AM BV2014 and 92,142 by MPM OIF."}],"balance_after":622579,"source":{"system":"sec-edgar","filing":"0001134657-26-000015","document":"form4-05292026_100543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000015/form4-05292026_100543.xml","form_type":"4"}},{"id":759075,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T22:51:47.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":27698,"price":0.46,"value":12741.08,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 2,968 by AM LLC, 18,736 by BV 2014, 1,250 by BV 2014(B), 645 by AM BV2014 and 4,099 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.455 to $0.4858 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 70,189 by AM LLC, 443,178 by BV 2014, 29,557 by BV 2014(B), 15,251 by AM BV2014 and 96,960 by MPM OIF."}],"balance_after":655135,"source":{"system":"sec-edgar","filing":"0001134657-26-000015","document":"form4-05292026_100543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000015/form4-05292026_100543.xml","form_type":"4"}},{"id":759074,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T22:51:47.000Z","date":"2026-05-27","kind":"sale","planned":true,"acquired":false,"shares":80852,"price":0.48,"value":38808.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 8,663 by MPM Asset Management LLC (\"AM LLC\"), 54,692 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 3,648 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,883 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 11,966 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.46 to $0.49705 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 73,157 by AM LLC, 461,914 by BV 2014, 30,807 by BV 2014(B), 15,896 by AM BV2014 and 101,059 by MPM OIF."}],"balance_after":682833,"source":{"system":"sec-edgar","filing":"0001134657-26-000015","document":"form4-05292026_100543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000015/form4-05292026_100543.xml","form_type":"4"}},{"id":764230,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T22:18:01.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":67950,"price":0.47,"value":31936.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 7,280 by AM LLC, 45,965 by BV 2014, 3,066 by BV 2014(B), 1,582 by AM BV2014 and 10,057 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4436 to $0.4826 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 81,820 by AM LLC, 516,606 by BV 2014, 34,455 by BV 2014(B), 17,779 by AM BV2014 and 113,025 by MPM OIF."}],"balance_after":763685,"source":{"system":"sec-edgar","filing":"0001134657-26-000014","document":"form4-05262026_100557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000014/form4-05262026_100557.xml","form_type":"4"}},{"id":764229,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T22:18:01.000Z","date":"2026-05-22","kind":"sale","planned":true,"acquired":false,"shares":87425,"price":0.45,"value":39341.25,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 9,367 by AM LLC, 59,139 by BV 2014, 3,944 by BV 2014(B), 2,036 by AM BV2014 and 12,939 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.42 to $0.4614 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 89,100 by AM LLC, 562,571 by BV 2014, 37,521 by BV 2014(B), 19,361 by AM BV2014 and 123,082 by MPM OIF."}],"balance_after":831635,"source":{"system":"sec-edgar","filing":"0001134657-26-000014","document":"form4-05262026_100557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000014/form4-05262026_100557.xml","form_type":"4"}},{"id":764228,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T22:18:01.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":36387,"price":0.42,"value":15282.54,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,899 by MPM Asset Management LLC (\"AM LLC\"), 24,614 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,642 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 847 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 5,385 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4126 to $0.4426 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 98,467 by AM LLC, 621,710 by BV 2014, 41,465 by BV 2014(B), 21,397 by AM BV2014 and 136,021 by MPM OIF."}],"balance_after":919060,"source":{"system":"sec-edgar","filing":"0001134657-26-000014","document":"form4-05262026_100557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000014/form4-05262026_100557.xml","form_type":"4"}},{"id":770352,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T22:08:29.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":85895,"price":0.43,"value":36934.85,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 9,203 by AM LLC, 58,105 by BV 2014, 3,875 by BV 2014(B), 2,000 by AM BV2014 and 12,712 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.40905 to $0.4455 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 102,366 by AM LLC, 646,324 by BV 2014, 43,107 by BV 2014(B), 22,244 by AM BV2014 and 141,406 by MPM OIF."}],"balance_after":955447,"source":{"system":"sec-edgar","filing":"0001134657-26-000012","document":"form4-05202026_100525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000012/form4-05202026_100525.xml","form_type":"4"}},{"id":770351,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T22:08:29.000Z","date":"2026-05-19","kind":"sale","planned":true,"acquired":false,"shares":62970,"price":0.45,"value":28336.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 6,747 by AM LLC, 42,596 by BV 2014, 2,841 by BV 2014(B), 1,466 by AM BV2014 and 9,320 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4243 to $0.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 111,569 by AM LLC, 704,429 by BV 2014, 46,982 by BV 2014(B), 24,244 by AM BV2014 and 154,118 by MPM OIF."}],"balance_after":1041342,"source":{"system":"sec-edgar","filing":"0001134657-26-000012","document":"form4-05202026_100525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000012/form4-05202026_100525.xml","form_type":"4"}},{"id":770350,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T22:08:29.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":22184,"price":0.5,"value":11092.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 2,377 by MPM Asset Management LLC (\"AM LLC\"), 15,006 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,001 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 517 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 3,283 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4931 to $0.5059 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 118,316 by AM LLC, 747,025 by BV 2014, 49,823 by BV 2014(B), 25,710 by AM BV2014 and 163,438 by MPM OIF."}],"balance_after":1104312,"source":{"system":"sec-edgar","filing":"0001134657-26-000012","document":"form4-05202026_100525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000012/form4-05202026_100525.xml","form_type":"4"}},{"id":781221,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-13T20:06:32.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":44679,"price":0.54,"value":24126.66,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,787 by MPM Asset Management LLC (\"AM LLC\"), 30,223 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,016 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,040 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 6,613 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5077 to $0.61 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 120,693 by AM LLC, 762,031 by BV 2014, 50,824 by BV 2014(B), 26,227 by AM BV2014 and 166,721 by MPM OIF."}],"balance_after":1126496,"source":{"system":"sec-edgar","filing":"0001134657-26-000011","document":"form4-05132026_080528.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000011/form4-05132026_080528.xml","form_type":"4"}},{"id":782990,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T23:47:42.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":67885,"price":0.64,"value":43446.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 7,273 by AM LLC, 45,921 by BV 2014, 3,063 by BV 2014(B), 1,581 by AM BV2014 and 10,047 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6286 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 125,480 by AM LLC, 792,254 by BV 2014, 52,840 by BV 2014(B), 27,267 by AM BV2014 and 173,334 by MPM OIF."}],"balance_after":1171175,"source":{"system":"sec-edgar","filing":"0001134657-26-000010","document":"form4-05122026_110537.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000010/form4-05122026_110537.xml","form_type":"4"}},{"id":782989,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T23:47:42.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":33948,"price":0.67,"value":22745.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,637 by AM LLC, 22,965 by BV 2014, 1,532 by BV 2014(B), 790 by AM BV2014 and 5,024 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.7002 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 132,753 by AM LLC, 838,175 by BV 2014, 55,903 by BV 2014(B), 28,848 by AM BV2014 and 183,381 by MPM OIF."}],"balance_after":1239060,"source":{"system":"sec-edgar","filing":"0001134657-26-000010","document":"form4-05122026_110537.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000010/form4-05122026_110537.xml","form_type":"4"}},{"id":782988,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T23:47:42.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":305741,"price":0.7,"value":214018.7,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 32,757 by MPM Asset Management LLC (\"AM LLC\"), 206,820 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 13,795 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 7,119 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 45,250 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6183 to $0.7668 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 136,390 by AM LLC, 861,140 by BV 2014, 57,435 by BV 2014(B), 29,638 by AM BV2014 and 188,405 by MPM OIF."}],"balance_after":1273008,"source":{"system":"sec-edgar","filing":"0001134657-26-000010","document":"form4-05122026_110537.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000010/form4-05122026_110537.xml","form_type":"4"}},{"id":782145,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T22:26:28.000Z","date":"2026-05-12","kind":"sale","planned":false,"acquired":false,"shares":6719,"price":0.64,"value":4300.16,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":406282,"source":{"system":"sec-edgar","filing":"0001231919-26-000485","document":"form4-05122026_100521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000485/form4-05122026_100521.xml","form_type":"4"}},{"id":782144,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T22:26:28.000Z","date":"2026-05-12","kind":"sale","planned":false,"acquired":false,"shares":94432,"price":0.64,"value":60436.48,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":5709858,"source":{"system":"sec-edgar","filing":"0001231919-26-000485","document":"form4-05122026_100521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000485/form4-05122026_100521.xml","form_type":"4"}},{"id":782143,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T22:26:28.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":5812,"price":0.67,"value":3894.04,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.71 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":413001,"source":{"system":"sec-edgar","filing":"0001231919-26-000485","document":"form4-05122026_100521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000485/form4-05122026_100521.xml","form_type":"4"}},{"id":782142,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T22:26:28.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":81678,"price":0.67,"value":54724.26,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.71 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":5804290,"source":{"system":"sec-edgar","filing":"0001231919-26-000485","document":"form4-05122026_100521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000485/form4-05122026_100521.xml","form_type":"4"}},{"id":782141,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T22:26:28.000Z","date":"2026-05-08","kind":"sale","planned":false,"acquired":false,"shares":25012,"price":0.71,"value":17758.52,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.76 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by Nexus Fund II."}],"balance_after":418813,"source":{"system":"sec-edgar","filing":"0001231919-26-000485","document":"form4-05122026_100521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000485/form4-05122026_100521.xml","form_type":"4"}},{"id":782140,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":3,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":4,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T22:26:28.000Z","date":"2026-05-08","kind":"sale","planned":false,"acquired":false,"shares":351514,"price":0.71,"value":249574.94,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.76 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein."}],"balance_after":5885968,"source":{"system":"sec-edgar","filing":"0001231919-26-000485","document":"form4-05122026_100521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000485/form4-05122026_100521.xml","form_type":"4"}},{"id":788736,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T22:22:22.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":79086,"price":0.63,"value":49824.18,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 8,473 by AM LLC, 53,499 by BV 2014, 3,568 by BV 2014(B), 1,841 by AM BV2014 and 11,705 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.667 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 169,147 by AM LLC, 1,067,960 by BV 2014, 71,230 by BV 2014(B), 36,757 by AM BV2014 and 233,655 by MPM OIF."}],"balance_after":1578749,"source":{"system":"sec-edgar","filing":"0001134657-26-000009","document":"form4-05072026_100518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000009/form4-05072026_100518.xml","form_type":"4"}},{"id":788735,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T22:22:22.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":14635,"price":0.66,"value":9659.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,568 by AM LLC, 9,900 by BV 2014, 660 by BV 2014(B), 341 by AM BV2014 and 2,166 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.7054 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 177,620 by AM LLC, 1,121,459 by BV 2014, 74,798 by BV 2014(B), 38,598 by AM BV2014 and 245,360 by MPM OIF."}],"balance_after":1657835,"source":{"system":"sec-edgar","filing":"0001134657-26-000009","document":"form4-05072026_100518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000009/form4-05072026_100518.xml","form_type":"4"}},{"id":788734,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T22:22:22.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":6860,"price":0.69,"value":4733.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 735 by MPM Asset Management LLC (\"AM LLC\"), 4,640 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 310 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 160 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 1,015 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6616 to $0.7253 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 179,188 by AM LLC, 1,131,359 by BV 2014, 75,458 by BV 2014(B), 38,939 by AM BV2014 and 247,526 by MPM OIF."}],"balance_after":1672470,"source":{"system":"sec-edgar","filing":"0001134657-26-000009","document":"form4-05072026_100518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000009/form4-05072026_100518.xml","form_type":"4"}},{"id":794273,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:00:00.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":47963,"price":0.72,"value":34533.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 5,139 by AM LLC, 32,445 by BV 2014, 2,164 by BV 2014(B), 1,117 by AM BV2014 and 7,098 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.7497 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 179,923 by AM LLC, 1,135,999 by BV 2014, 75,768 by BV 2014(B), 39,099 by AM BV2014 and 248,541 by MPM OIF."}],"balance_after":1679330,"source":{"system":"sec-edgar","filing":"0001134657-26-000008","document":"form4-05042026_090556.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000008/form4-05042026_090556.xml","form_type":"4"}},{"id":794272,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:00:00.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":58394,"price":0.73,"value":42627.62,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 6,256 by AM LLC, 39,501 by BV 2014, 2,635 by BV 2014(B), 1,360 by AM BV2014 and 8,642 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7011 to $0.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 185,062 by AM LLC, 1,168,444 by BV 2014, 77,932 by BV 2014(B), 40,216 by AM BV2014 and 255,639 by MPM OIF."}],"balance_after":1727293,"source":{"system":"sec-edgar","filing":"0001134657-26-000008","document":"form4-05042026_090556.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000008/form4-05042026_090556.xml","form_type":"4"}},{"id":794271,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:00:00.000Z","date":"2026-04-30","kind":"sale","planned":true,"acquired":false,"shares":168262,"price":0.72,"value":121148.64,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 18,028 by MPM Asset Management LLC (\"AM LLC\"), 113,821 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 7,592 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 3,918 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 24,903 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.688 to $0.7458 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 191,318 by AM LLC, 1,207,945 by BV 2014, 80,567 by BV 2014(B), 41,576 by AM BV2014 and 264,281 by MPM OIF."}],"balance_after":1785687,"source":{"system":"sec-edgar","filing":"0001134657-26-000008","document":"form4-05042026_090556.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000008/form4-05042026_090556.xml","form_type":"4"}},{"id":798123,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-29T23:16:48.000Z","date":"2026-04-29","kind":"sale","planned":true,"acquired":false,"shares":56559,"price":0.69,"value":39025.71,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,060 by AM LLC, 38,259 by BV 2014, 2,552 by BV 2014(B), 1,317 by AM BV2014 and 8,371 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.68 to $0.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 209,346 by AM LLC, 1,321,766 by BV 2014, 88,159 by BV 2014(B), 45,494 by AM BV2014 and 289,184 by MPM OIF."}],"balance_after":1953949,"source":{"system":"sec-edgar","filing":"0001134657-26-000007","document":"form4-04292026_110444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000007/form4-04292026_110444.xml","form_type":"4"}},{"id":798122,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-29T23:16:48.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":95412,"price":0.73,"value":69650.76,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 10,223 by AM LLC, 64,541 by BV 2014, 4,305 by BV 2014(B), 2,222 by AM BV2014 and 14,121 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.673 to $0.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 215,406 by AM LLC, 1,360,025 by BV 2014, 90,711 by BV 2014(B), 46,811 by AM BV2014 and 297,555 by MPM OIF."}],"balance_after":2010508,"source":{"system":"sec-edgar","filing":"0001134657-26-000007","document":"form4-04292026_110444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000007/form4-04292026_110444.xml","form_type":"4"}},{"id":798121,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-29T23:16:48.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":53940,"price":0.85,"value":45849.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 5,779 by MPM Asset Management LLC (\"AM LLC\"), 36,488 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,434 by MPM BIoVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,256 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 7,983 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.818 to $0.8788 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 225,629 by AM LLC, 1,424,566 by BV 2014, 95,016 by BV 2014(B), 49,033 by AM BV2014 and 311,676 by MPM OIF."}],"balance_after":2105920,"source":{"system":"sec-edgar","filing":"0001134657-26-000007","document":"form4-04292026_110444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000007/form4-04292026_110444.xml","form_type":"4"}},{"id":935676,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-20T21:07:44.000Z","date":"2026-01-16","kind":"sale","planned":true,"acquired":false,"shares":38782,"price":0.54,"value":20942.28,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,152 by MPM Asset Management LLC (\"AM LLC\"), 26,213 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,749 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 893 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 5,775 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.535 to $0.5495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 231,408 by AM LLC, 1,461,054 by BV 2014, 97,450 by BV 2014(B), 50,289 by AM BV2014 and 319,659 by MPM OIF."}],"balance_after":2159860,"source":{"system":"sec-edgar","filing":"0001134657-26-000006","document":"form4-01202026_090141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000006/form4-01202026_090141.xml","form_type":"4"}},{"id":938650,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-15T22:22:58.000Z","date":"2026-01-15","kind":"sale","planned":true,"acquired":false,"shares":37413,"price":0.55,"value":20577.15,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,002 by AM LLC, 25,285 by BV 2014, 1,686 by BV 2014(B), 872 by AM BV2014 and 5,568 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5305 to $0.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 235,560 by AM LLC, 1,487,267 by BV 2014, 99,199 by BV 2014(B), 51,182 by AM BV2014 and 325,434 by MPM OIF."}],"balance_after":2198642,"source":{"system":"sec-edgar","filing":"0001134657-26-000005","document":"form4-01152026_100154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000005/form4-01152026_100154.xml","form_type":"4"}},{"id":938649,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-15T22:22:58.000Z","date":"2026-01-14","kind":"sale","planned":true,"acquired":false,"shares":30616,"price":0.57,"value":17451.12,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,275 by AM LLC, 20,692 by BV 2014, 1,380 by BV 2014(B), 712 by AM BV2014 and 4,557 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5524 to $0.5857 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 239,562 by AM LLC, 1,512,552 by BV 2014, 100,885 by BV 2014(B), 52,054 by AM BV2014 and 331,002 by MPM OIF."}],"balance_after":2236055,"source":{"system":"sec-edgar","filing":"0001134657-26-000005","document":"form4-01152026_100154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000005/form4-01152026_100154.xml","form_type":"4"}},{"id":938648,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-15T22:22:58.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":43198,"price":0.55,"value":23758.9,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,621 by MPM Asset Management LLC (\"AM LLC\"), 29,195 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,947 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,006 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 6,429 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.53675 to $0.5697 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 242,837 by AM LLC, 1,533,244 by BV 2014, 102,265 by BV 2014(B), 52,766 by AM BV2014 and 335,559 by MPM OIF."}],"balance_after":2266671,"source":{"system":"sec-edgar","filing":"0001134657-26-000005","document":"form4-01152026_100154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000005/form4-01152026_100154.xml","form_type":"4"}},{"id":941291,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:09:43.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":58980,"price":0.57,"value":33618.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,309 by AM LLC, 39,861 by BV 2014, 2,659 by BV 2014(B), 1,373 by AM BV2014 and 8,778 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5608 to $0.606 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 247,458 by AM LLC, 1,562,439 by BV 2014, 104,212 by BV 2014(B), 53,772 by AM BV2014 and 341,988 by MPM OIF."}],"balance_after":2309869,"source":{"system":"sec-edgar","filing":"0001134657-26-000004","document":"form4-01122026_100138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000004/form4-01122026_100138.xml","form_type":"4"}},{"id":941290,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:09:43.000Z","date":"2026-01-09","kind":"sale","planned":true,"acquired":false,"shares":24678,"price":0.61,"value":15053.58,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 2,640 by AM LLC, 16,678 by BV 2014, 1,112 by BV 2014(B), 575 by AM BV2014 and 3,673 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6019 to $0.6583 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 253,767 by AM LLC, 1,602,300 by BV 2014, 106,871 by BV 2014(B), 55,145 by AM BV2014 and 350,766 by MPM OIF."}],"balance_after":2368849,"source":{"system":"sec-edgar","filing":"0001134657-26-000004","document":"form4-01122026_100138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000004/form4-01122026_100138.xml","form_type":"4"}},{"id":941289,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:09:43.000Z","date":"2026-01-08","kind":"sale","planned":true,"acquired":false,"shares":7716,"price":0.63,"value":4861.08,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 825 by MPM Asset Management LLC (\"AM LLC\"), 5,215 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 348 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 180 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 1,148 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6243 to $0.6368 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 256,407 by AM LLC, 1,618,978 by BV 2014, 107,983 by BV 2014(B), 55,720 by AM BV2014 and 354,439 by MPM OIF."}],"balance_after":2393527,"source":{"system":"sec-edgar","filing":"0001134657-26-000004","document":"form4-01122026_100138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000004/form4-01122026_100138.xml","form_type":"4"}},{"id":944972,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-07T22:12:49.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":11915,"price":0.64,"value":7625.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 1,275 by AM LLC, 8,053 by BV 2014, 537 by BV 2014(B), 277 by AM BV2014 and 1,773 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6276 to $0.6598 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 257,232 by AM LLC, 1,624,193 by BV 2014, 108,331 by BV 2014(B), 55,900 by AM BV2014 and 355,587 by MPM OIF."}],"balance_after":2401243,"source":{"system":"sec-edgar","filing":"0001134657-26-000002","document":"form4-01072026_100145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000002/form4-01072026_100145.xml","form_type":"4"}},{"id":944971,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-07T22:12:49.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":40761,"price":0.65,"value":26494.65,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,361 by AM LLC, 27,548 by BV 2014, 1,837 by BV 2014(B), 948 by AM BV2014 and 6,067 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.6599 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 258,507 by AM LLC, 1,632,246 by BV 2014, 108,868 by BV 2014(B), 56,177 by AM BV2014 and 357,360 by MPM OIF."}],"balance_after":2413158,"source":{"system":"sec-edgar","filing":"0001134657-26-000002","document":"form4-01072026_100145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000002/form4-01072026_100145.xml","form_type":"4"}},{"id":944970,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-07T22:12:49.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":18378,"price":0.64,"value":11761.92,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 1,966 by MPM Asset Management LLC (\"AM LLC\"), 12,420 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 828 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 429 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 2,735 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.63435 to $0.6549 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 262,868 by AM LLC, 1,659,794 by BV 2014, 110,705 by BV 2014(B), 57,125 by AM BV2014 and 363,427 by MPM OIF."}],"balance_after":2453919,"source":{"system":"sec-edgar","filing":"0001134657-26-000002","document":"form4-01072026_100145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000002/form4-01072026_100145.xml","form_type":"4"}},{"id":955469,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T22:32:32.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":18568,"price":0.63,"value":11697.84,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 1,986 by AM LLC, 12,549 by BV 2014, 837 by BV 2014(B), 432 by AM BV2014 and 2,764 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.6499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 264,834 by AM LLC, 1,672,214 by BV 2014, 111,533 by BV 2014(B), 57,554 by AM BV2014 and 366,162 by MPM OIF."}],"balance_after":2472297,"source":{"system":"sec-edgar","filing":"0001134657-26-000001","document":"form4-01022026_100128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000001/form4-01022026_100128.xml","form_type":"4"}},{"id":955468,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T22:32:32.000Z","date":"2025-12-31","kind":"sale","planned":true,"acquired":false,"shares":24962,"price":0.62,"value":15476.44,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 2,670 by AM LLC, 16,870 by BV 2014, 1,125 by BV 2014(B), 582 by AM BV2014 and 3,715 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6038 to $0.6359 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 266,820 by AM LLC, 1,684,763 by BV 2014, 112,370 by BV 2014(B), 57,986 by AM BV2014 and 368,926 by MPM OIF."}],"balance_after":2490865,"source":{"system":"sec-edgar","filing":"0001134657-26-000001","document":"form4-01022026_100128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000001/form4-01022026_100128.xml","form_type":"4"}},{"id":955467,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T22:32:32.000Z","date":"2025-12-30","kind":"sale","planned":true,"acquired":false,"shares":34847,"price":0.61,"value":21256.67,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,728 by MPM Asset Management LLC (\"AM LLC\"), 23,551 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,571 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 811 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 5,186 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6085 to $0.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 269,490 by AM LLC, 1,701,633 by BV 2014, 113,495 by BV 2014(B), 58,568 by AM BV2014 and 372,641 by MPM OIF."}],"balance_after":2515827,"source":{"system":"sec-edgar","filing":"0001134657-26-000001","document":"form4-01022026_100128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465726000001/form4-01022026_100128.xml","form_type":"4"}},{"id":958558,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T22:27:50.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":108606,"price":0.61,"value":66249.66,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F15","text":"The shares were sold as follows: 11,618 by AM LLC, 73,401 by BV 2014, 4,896 by BV 2014(B), 2,526 by AM BV2014 and 16,165 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.58955 to $0.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"The shares are held as follows: 273,218 by AM LLC, 1,725,184 by BV 2014, 115,066 by BV 2014(B), 59,379 by AM BV2014 and 377,827 by MPM OIF."}],"balance_after":2550674,"source":{"system":"sec-edgar","filing":"0001134657-25-000018","document":"form4-12292025_101245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000018/form4-12292025_101245.xml","form_type":"4"}},{"id":958557,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T22:27:50.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":35632,"price":0.63,"value":22448.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 3,812 by AM LLC, 24,082 by BV 2014, 1,606 by BV 2014(B), 829 by AM BV2014 and 5,303 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6165 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 284,836 by AM LLC, 1,798,585 by BV 2014, 119,962 by BV 2014(B), 61,905 by AM BV2014 and 393,992 by MPM OIF."}],"balance_after":2659280,"source":{"system":"sec-edgar","filing":"0001134657-25-000018","document":"form4-12292025_101245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000018/form4-12292025_101245.xml","form_type":"4"}},{"id":958556,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T22:27:50.000Z","date":"2025-12-24","kind":"sale","planned":true,"acquired":false,"shares":16310,"price":0.65,"value":10601.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 1,745 by AM LLC, 11,023 by BV 2014, 735 by BV 2014(B), 379 by AM BV2014 and 2,428 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6337 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 288,648 by AM LLC, 1,822,667 by BV 2014, 121,568 by BV 2014(B), 62,734 by AM BV2014 and 399,295 by MPM OIF."}],"balance_after":2694912,"source":{"system":"sec-edgar","filing":"0001134657-25-000018","document":"form4-12292025_101245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000018/form4-12292025_101245.xml","form_type":"4"}},{"id":958555,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T22:27:50.000Z","date":"2025-12-23","kind":"sale","planned":true,"acquired":false,"shares":71428,"price":0.63,"value":44999.64,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 7,641 by AM LLC, 48,274 by BV 2014, 3,220 by BV 2014(B), 1,662 by AM BV2014 and 10,631 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.61 to $0.6728 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 290,393 by AM LLC, 1,833,690 by BV 2014, 122,303 by BV 2014(B), 63,113 by AM BV2014 and 401,723 by MPM OIF."}],"balance_after":2711222,"source":{"system":"sec-edgar","filing":"0001134657-25-000018","document":"form4-12292025_101245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000018/form4-12292025_101245.xml","form_type":"4"}},{"id":958554,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T22:27:50.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":59307,"price":0.69,"value":40921.83,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 6,344 by MPM Asset Management LLC (\"AM LLC\"), 40,082 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,673 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,381 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 8,827 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6596 to $0.7341 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 298,034 by AM LLC, 1,881,964 by BV 2014, 125,523 by BV 2014(B), 64,775 by AM BV2014 and 412,354 by MPM OIF."}],"balance_after":2782650,"source":{"system":"sec-edgar","filing":"0001134657-25-000018","document":"form4-12292025_101245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000018/form4-12292025_101245.xml","form_type":"4"}},{"id":965629,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-17T23:28:53.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":9983,"price":1.14,"value":11380.62,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 1,068 by AM LLC, 6,747 by BV 2014, 450 by BV 2014(B), 232 by AM BV2014 and 1,486 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.095 to $1.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 304,378 by AM LLC, 1,922,046 by BV 2014, 128,196 by BV 2014(B), 66,156 by AM BV2014 and 421,181 by MPM OIF."}],"balance_after":2841957,"source":{"system":"sec-edgar","filing":"0001134657-25-000017","document":"form4-12172025_111249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000017/form4-12172025_111249.xml","form_type":"4"}},{"id":965628,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-17T23:28:53.000Z","date":"2025-12-16","kind":"sale","planned":true,"acquired":false,"shares":14548,"price":1.05,"value":15275.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,556 by AM LLC, 9,832 by BV 2014, 656 by BV 2014(B), 339 by AM BV2014 and 2,165 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 305,446 by AM LLC, 1,928,793 by BV 2014, 128,646 by BV 2014(B), 66,388 by AM BV2014 and 422,667 by MPM OIF."}],"balance_after":2851940,"source":{"system":"sec-edgar","filing":"0001134657-25-000017","document":"form4-12172025_111249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000017/form4-12172025_111249.xml","form_type":"4"}},{"id":965627,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-17T23:28:53.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":23640,"price":1.07,"value":25294.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 2,529 by MPM Asset Management LLC (\"AM LLC\"), 15,977 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,066 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 550 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 3,518 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 307,002 by AM LLC, 1,938,625 by BV 2014, 129,302 by BV 2014(B), 66,727 by AM BV2014 and 424,832 by MPM OIF."}],"balance_after":2866488,"source":{"system":"sec-edgar","filing":"0001134657-25-000017","document":"form4-12172025_111249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000017/form4-12172025_111249.xml","form_type":"4"}},{"id":971682,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-12T22:32:31.000Z","date":"2025-12-12","kind":"sale","planned":true,"acquired":false,"shares":17858,"price":1.08,"value":19286.64,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 1,910 by AM LLC, 12,069 by BV 2014, 805 by BV 2014(B), 416 by AM BV2014 and 2,658 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.06 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 309,531 by AM LLC, 1,954,602 by BV 2014, 130,368 by BV 2014(B),67,277 by AM BV2014 and 428,350 by MPM OIF."}],"balance_after":2890128,"source":{"system":"sec-edgar","filing":"0001134657-25-000016","document":"form4-12122025_101227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000016/form4-12122025_101227.xml","form_type":"4"}},{"id":971681,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-12T22:32:31.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":28009,"price":1.07,"value":29969.63,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 2,996 by AM LLC, 18,930 by BV 2014, 1,263 by BV 2014(B), 651 by AM BV2014 and 4,169 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 311,441 by AM LLC, 1,966,671 by BV 2014, 131,173 by BV 2014(B), 67,693 by AM BV2014 and 431,008 by MPM OIF."}],"balance_after":2907986,"source":{"system":"sec-edgar","filing":"0001134657-25-000016","document":"form4-12122025_101227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000016/form4-12122025_101227.xml","form_type":"4"}},{"id":971680,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-12T22:32:31.000Z","date":"2025-12-10","kind":"sale","planned":true,"acquired":false,"shares":37104,"price":1.06,"value":39330.24,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,969 by MPM Asset Management LLC (\"AM LLC\"), 25,077 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,673 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 863 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\") and 5,522 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9742 to $1.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 314,437 by AM LLC, 1,985,601 by BV 2014, 132,436 by BV 2014(B), 68,344 by AM BV2014 and 435,177 by MPM OIF."}],"balance_after":2935995,"source":{"system":"sec-edgar","filing":"0001134657-25-000016","document":"form4-12122025_101227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000016/form4-12122025_101227.xml","form_type":"4"}},{"id":976485,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T22:07:35.000Z","date":"2025-12-09","kind":"sale","planned":true,"acquired":false,"shares":44570,"price":1.01,"value":45015.7,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,768 by AM LLC, 30,123 by BV 2014, 2,009 by BV 2014(B), 1,036 by AM BV2014 and 6,634 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.99 to $1.025 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 318,406 by AM LLC, 2,010,678 by BV 2014, 134,109 by BV 2014(B), 69,207 by AM BV2014 and 440,699 by MPM OIF."}],"balance_after":2973099,"source":{"system":"sec-edgar","filing":"0001134657-25-000015","document":"form4-12092025_101231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000015/form4-12092025_101231.xml","form_type":"4"}},{"id":976484,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T22:07:35.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":34041,"price":0.99,"value":33700.59,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,642 by AM LLC, 23,006 by BV 2014, 1,534 by BV 2014(B), 792 by AM BV2014 and 5,067 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9582 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 323,174 by AM LLC, 2,040,801 by BV 2014, 136,118 by BV 2014(B), 70,243 by AM BV2014 and 447,333 by MPM OIF."}],"balance_after":3017669,"source":{"system":"sec-edgar","filing":"0001134657-25-000015","document":"form4-12092025_101231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000015/form4-12092025_101231.xml","form_type":"4"}},{"id":976483,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T22:07:35.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":16568,"price":0.97,"value":16070.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 1,772 by MPM Asset Management LLC (\"AM LLC\"), 11,197 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 747 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 386 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\") and 2,466 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9434 to $0.9863 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 326,816 by AM LLC, 2,063,807 by BV 2014, 137,652 by BV 2014(B), 71,035 by AM BV2014 and 452,400 by MPM OIF."}],"balance_after":3051710,"source":{"system":"sec-edgar","filing":"0001134657-25-000015","document":"form4-12092025_101231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000015/form4-12092025_101231.xml","form_type":"4"}},{"id":980557,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-04T23:20:30.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":53416,"price":0.97,"value":51813.52,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014 and 7,950 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014 and 454,866 by MPM OIF."}],"balance_after":3068278,"source":{"system":"sec-edgar","filing":"0001134657-25-000014","document":"form4-12042025_111226.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000014/form4-12042025_111226.xml","form_type":"4"}},{"id":980556,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-04T23:20:30.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":36726,"price":0.87,"value":31951.62,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014 and 5,466 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014 and 462,816 by MPM OIF."}],"balance_after":3121694,"source":{"system":"sec-edgar","filing":"0001134657-25-000014","document":"form4-12042025_111226.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000014/form4-12042025_111226.xml","form_type":"4"}},{"id":980555,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-04T23:20:30.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":38043,"price":0.89,"value":33858.27,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,070 by MPM Asset Management LLC (\"AM LLC\"), 25,712 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,715 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 884 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\") and 5,662 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014 and 468,282 by MPM OIF."}],"balance_after":3158420,"source":{"system":"sec-edgar","filing":"0001134657-25-000014","document":"form4-12042025_111226.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000014/form4-12042025_111226.xml","form_type":"4"}},{"id":979980,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":2,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":3,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":4,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":5,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:19:45.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":83230,"price":0.97,"value":80733.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of\nBV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of\nthe securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology."}],"balance_after":4784111,"source":{"system":"sec-edgar","filing":"0001231919-25-000575","document":"form4-12042025_111239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609492/000123191925000575/form4-12042025_111239.xml","form_type":"4"}},{"id":979979,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":2,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":3,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":4,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":5,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:19:45.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":57225,"price":0.87,"value":49785.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of\nBV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of\nthe securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology."}],"balance_after":4867341,"source":{"system":"sec-edgar","filing":"0001231919-25-000575","document":"form4-12042025_111239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609492/000123191925000575/form4-12042025_111239.xml","form_type":"4"}},{"id":979978,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":2,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":3,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":4,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":5,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:19:45.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":59277,"price":0.89,"value":52756.53,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,070 by MPM Asset Management LLC (\"AM LLC\"), 25,712 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,715 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 884 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,662 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,234 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of\nBV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of\nthe securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology."}],"balance_after":4924566,"source":{"system":"sec-edgar","filing":"0001231919-25-000575","document":"form4-12042025_111239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609492/000123191925000575/form4-12042025_111239.xml","form_type":"4"}},{"id":980574,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":83230,"price":0.97,"value":80733.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology."}],"balance_after":4784111,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":980573,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":57225,"price":0.87,"value":49785.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology."}],"balance_after":4867341,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":980572,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":59277,"price":0.89,"value":52756.53,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,070 by MPM Asset Management LLC (\"AM LLC\"), 25,712 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,715 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 884 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,662 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,234 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology."}],"balance_after":4924566,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":985363,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:13:37.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":39096,"price":0.94,"value":36750.24,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014 and 5,819 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014 and 473,944 by MPM OIF."}],"balance_after":3196463,"source":{"system":"sec-edgar","filing":"0001134657-25-000013","document":"form4-12012025_111233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000013/form4-12012025_111233.xml","form_type":"4"}},{"id":985362,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:13:37.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":13014,"price":0.99,"value":12883.86,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014 and 1,937 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014 and 479,763 by MPM OIF."}],"balance_after":3235559,"source":{"system":"sec-edgar","filing":"0001134657-25-000013","document":"form4-12012025_111233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000013/form4-12012025_111233.xml","form_type":"4"}},{"id":985361,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:13:37.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":38978,"price":0.98,"value":38198.44,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,170 by MPM Asset Management LLC (\"AM LLC\"), 26,343 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,757 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 907 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\") and 5,801 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014 and 481,700 by MPM OIF."}],"balance_after":3248573,"source":{"system":"sec-edgar","filing":"0001134657-25-000013","document":"form4-12012025_111233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000013/form4-12012025_111233.xml","form_type":"4"}},{"id":984820,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":2,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":3,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":4,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":5,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:12:45.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":60917,"price":0.94,"value":57261.98,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of\nBV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of\nthe securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology."}],"balance_after":4983843,"source":{"system":"sec-edgar","filing":"0001231919-25-000565","document":"form4-12012025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609492/000123191925000565/form4-12012025_111237.xml","form_type":"4"}},{"id":984819,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":2,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":3,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":4,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":5,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:12:45.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":20277,"price":0.99,"value":20074.23,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of\nBV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of\nthe securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology"}],"balance_after":5044760,"source":{"system":"sec-edgar","filing":"0001231919-25-000565","document":"form4-12012025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609492/000123191925000565/form4-12012025_111237.xml","form_type":"4"}},{"id":984818,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":2,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":3,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":4,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":5,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:12:45.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":60733,"price":0.98,"value":59518.34,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,170 by MPM Asset Management LLC (\"AM LLC\"), 26,343 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,757 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 907 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,801 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,755 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of\nBV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of\nthe securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology"}],"balance_after":5065037,"source":{"system":"sec-edgar","filing":"0001231919-25-000565","document":"form4-12012025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609492/000123191925000565/form4-12012025_111237.xml","form_type":"4"}},{"id":985366,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":60917,"price":0.94,"value":57261.98,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology."}],"balance_after":4983843,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":985365,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":20277,"price":0.99,"value":20074.23,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology."}],"balance_after":5044760,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":985364,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":60733,"price":0.98,"value":59518.34,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,170 by MPM Asset Management LLC (\"AM LLC\"), 26,343 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,757 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 907 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,801 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,755 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology."}],"balance_after":5065037,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":989036,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:05:25.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":27297,"price":0.92,"value":25113.24,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014 and 4,063 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014 and 487,501 by MPM OIF."}],"balance_after":3287551,"source":{"system":"sec-edgar","filing":"0001134657-25-000012","document":"form4-11252025_111121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000012/form4-11252025_111121.xml","form_type":"4"}},{"id":989035,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:05:25.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":56992,"price":0.98,"value":55852.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014 and 8,483 by MPM OIF."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014 and 491,564 by MPM OIF."}],"balance_after":3314848,"source":{"system":"sec-edgar","filing":"0001134657-25-000012","document":"form4-11252025_111121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000012/form4-11252025_111121.xml","form_type":"4"}},{"id":989034,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2480,"kind":"person","name":"EVNIN LUKE","position":1,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:05:25.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":41287,"price":0.83,"value":34268.21,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,417 by MPM Asset Management LLC (\"AM LLC\"), 27,904 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,861 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 960 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\") and 6,145 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM\nBV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the\nsecurities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014 and 500,047 by MPM OIF."}],"balance_after":3371840,"source":{"system":"sec-edgar","filing":"0001134657-25-000012","document":"form4-11252025_111121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134657/000113465725000012/form4-11252025_111121.xml","form_type":"4"}}],"next_cursor":"2025-11-25T23:05:25.000000Z,989034"}